Latest News

Clinical Trial Results 23 October 2026

Clinical Trial Results 23 October 2026

The clinical trial results 23 October 2026 cover non-infectious uveitis, hidradenitis suppurativa, IgA nephropathy, wet AMD and metastatic colorectal cancer. Priovant’s brepocitinib met its primary endpoint in two Phase 3 trials in non-infectious uveitis. AbbVie’s...

read more

Latest News

From EHR Data to Real-World Evidence: Health IT Meets R&D

From EHR Data to Real-World Evidence: Health IT Meets R&D

For most of their existence, electronic health records have been treated as administrative infrastructure, a place to document a visit, justify a claim and satisfy a compliance requirement. That framing no longer reflects their potential. The same records that...

read more
Oral GLP-1 Manufacturing: Can Supply Meet Demand?

Oral GLP-1 Manufacturing: Can Supply Meet Demand?

Oral GLP-1 manufacturing is now the binding constraint in obesity, not patient acceptance. The question is peptide capacity, tabletting lines and capital committed ahead of demand. Two weight loss tablets have reshaped the obesity market in under a year. Novo...

read more

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

Prostate Cancer Screening: What You Need to Know

Prostate Cancer Screening: What You Need to Know

Prostate cancer is one of the most common cancers affecting men worldwide. Across the UK, Europe and the United States, it remains a leading cause of cancer diagnosis in men and a significant contributor to cancer related mortality. Despite its prevalence, prostate...

read more
Lego for Biotech Labs

Lego for Biotech Labs

How Modular Hardware Is Breaking Decades of Vendor Lock-In There’s a running joke among biotech lab managers that goes something like this: You don’t buy a bioreactor. You buy a relationship. A very expensive, very locked-in relationship. It’s funny because it’s...

read more
J&J Axes Eczema Drug From $1.25B Acquisition

J&J Axes Eczema Drug From $1.25B Acquisition

Johnson & Johnson has discontinued development of an eczema treatment that was a central asset in a biotechnology acquisition valued at up to 1.25 billion US dollars, following a recent internal portfolio review. The decision highlights the ongoing scientific and...

read more
7,000 Steps a Day May Improve Brain and Reduce Disease Risk

7,000 Steps a Day May Improve Brain and Reduce Disease Risk

Walking around 7,000 steps each day could help sharpen cognition and shield against a variety of chronic illnesses, according to a major new analysis. This target may be more attainable, yet still effective, than the widely publicised 10,000 step goal. Published in...

read more
The Boom in Life Sciences in India

The Boom in Life Sciences in India

India is emerging as one of the most dynamic life sciences markets in the world. Long recognised for its strength in pharmaceuticals and generics, the country is now experiencing a broader life sciences boom that spans biotechnology, vaccines, medical devices,...

read more
Mapping a Single Neuron

Mapping a Single Neuron

This visualization from the Lichtman Lab and Google Connectomics captures one of the most detailed looks we’ve ever had at a single cortical neuron. What you’re seeing isn’t an artist’s rendering — it’s a true 3D reconstruction built from electron microscopy, stitched...

read more
Prostate Cancer Screening: What You Need to Know

Prostate Cancer Screening: What You Need to Know

Prostate cancer is one of the most common cancers affecting men worldwide. Across the UK, Europe and the United States, it remains a leading cause of cancer diagnosis in men and a significant contributor to cancer related mortality. Despite its prevalence, prostate...

read more
Lego for Biotech Labs

Lego for Biotech Labs

How Modular Hardware Is Breaking Decades of Vendor Lock-In There’s a running joke among biotech lab managers that goes something like this: You don’t buy a bioreactor. You buy a relationship. A very expensive, very locked-in relationship. It’s funny because it’s...

read more
J&J Axes Eczema Drug From $1.25B Acquisition

J&J Axes Eczema Drug From $1.25B Acquisition

Johnson & Johnson has discontinued development of an eczema treatment that was a central asset in a biotechnology acquisition valued at up to 1.25 billion US dollars, following a recent internal portfolio review. The decision highlights the ongoing scientific and...

read more
7,000 Steps a Day May Improve Brain and Reduce Disease Risk

7,000 Steps a Day May Improve Brain and Reduce Disease Risk

Walking around 7,000 steps each day could help sharpen cognition and shield against a variety of chronic illnesses, according to a major new analysis. This target may be more attainable, yet still effective, than the widely publicised 10,000 step goal. Published in...

read more
The Boom in Life Sciences in India

The Boom in Life Sciences in India

India is emerging as one of the most dynamic life sciences markets in the world. Long recognised for its strength in pharmaceuticals and generics, the country is now experiencing a broader life sciences boom that spans biotechnology, vaccines, medical devices,...

read more
Mapping a Single Neuron

Mapping a Single Neuron

This visualization from the Lichtman Lab and Google Connectomics captures one of the most detailed looks we’ve ever had at a single cortical neuron. What you’re seeing isn’t an artist’s rendering — it’s a true 3D reconstruction built from electron microscopy, stitched...

read more

Featured Articles

DNA double helix beside a microscope, test tubes and a pipette over a petri dish, representing life science publishing

Life Science Publishing: Our First Year, and Where You Fit In

Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...
FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

UK Winter Flu 2025: Current Trends and Vaccine Advice

UK Winter Flu 2025: Current Trends and Vaccine Advice

As the UK enters the heart of the 2025 to 2026 winter respiratory season, influenza flu is emerging as a major public health challenge, with cases rising earlier and more sharply than usual. Health services are already under strain, and experts are urging the public...

read more
Metabolic Myths That Hold you Back

Metabolic Myths That Hold you Back

In the age of endless diet tips and health hacks, metabolic health has become one of the most misunderstood topics. People try hard… they cut calories, walk more, sleep less, snack less… yet nothing changes. The problem isn’t effort. It’s misinformation. Metabolic...

read more
Are Mega-Deals Back for Real?

Are Mega-Deals Back for Real?

By early Q4 2025, global pharma M&A had already crossed $70B in announced value, driven heavily by a handful of mega-deals, more than 2024, and tracking toward the highest levels since the post-2015 boom. Unlike 2023–24, this wave isn’t driven by small tuck-ins....

read more
AI Drug Discovery Moves from Hype to Measurable Output

AI Drug Discovery Moves from Hype to Measurable Output

Artificial intelligence is increasingly being judged on clinical progress and tangible outcomes, not just models and algorithms. Once a speculative concept, AI-driven drug discovery is now generating real-world data, advancing molecules into human studies, reshaping...

read more
The Science Behind Sleep, Exercise and Hydration Targets

The Science Behind Sleep, Exercise and Hydration Targets

For decades, public health messaging has revolved around simple numerical targets. Get eight hours of sleep. Exercise for 150 minutes a week. Drink eight glasses of water a day. These guidelines are easy to remember and widely promoted, but they also raise an...

read more
Must-Track Biomarkers

Must-Track Biomarkers

The Numbers That Reveal Your Metabolic Health Today… and Your Risk Tomorrow Most people rely on weight or BMI to judge their health… yet neither tells you how your metabolism is actually working. True metabolic health comes from understanding what’s happening inside...

read more
Gene and RNA Therapies Gain Momentum in Obesity Treatment

Gene and RNA Therapies Gain Momentum in Obesity Treatment

The field of obesity treatment is expanding beyond GLP 1 receptor agonists as a growing wave of gene modulating and RNA based therapies emerges. These next generation programmes aim to address fat accumulation, particularly visceral fat and metabolic dysfunction,...

read more
How Neurons Help Cancer Spread

How Neurons Help Cancer Spread

One of the biggest surprises in modern cancer biology is that tumors are wired with nerves—and cancers with more nerve fibers tend to be more aggressive. A new study finally explains why. The Key Finding Neurons actively transfer their mitochondria — the cell’s energy...

read more

Further News

Medicare GLP-1 Bridge: Who Qualifies and Who Does Not

The Medicare GLP-1 Bridge launched on 1 July 2026, opening a new pathway for eligible Medicare Part D beneficiaries to access weight management medications at a fixed monthly copay of $50. For clinicians navigating GLP-1 Bridge eligibility criteria, the prior...

The Next Public Health Playbook: Why Trust Matters More Than Ever

The current news cycle is dominated by new and exotic-sounding organisms and chemicals: PFOS, bisphenols, phthalates, Mpox, New World screwworm, Andes hantavirus, Ebola bundibugyo, Borrelia burgdorferi, dengue, and chikungunya. What do they have in common? They are...

Clinical Trials Roundup | 10 July 2026

Roche’s divarasib demonstrates superiority over approved KRAS G12C inhibitors in the Phase 3 Krascendo 1 head-to-head lung cancer trial, Vera Therapeutics’ Trutakna receives FDA accelerated approval as the first BAFF/APRIL inhibitor for IgA nephropathy, Rhythm...

Adipose Tissue Isn’t Just Storage: Fat as an Endocrine and Immune Organ

For much of the 20th century, body fat was viewed mainly as the body's energy reservoir—a passive tissue that stored excess calories for future use. While this remains an important function of adipose tissue, research over the past few decades has revealed a far more...

FDA Drug Approval Decisions to Watch: July and August 2026

The second half of 2026 is shaping up to be one of the most consequential periods for FDA drug approval decisions in recent memory. Between mid-July and late August, the US Food and Drug Administration faces a succession of Prescription Drug User Fee Act target action...

New Research On the Next Phase in Protecting Muscle During GLP-1 Treatment

When I wrote previously for this publication about the gap between GLP-1 prescribing rates and the clinical conversation around lean muscle preservation, the argument centred on a simple premise: weight loss is not fat loss, and the clinical infrastructure around...

Atacicept FDA Approval: Trutakna Cleared for IgAN

The atacicept FDA approval that the nephrology community had been anticipating since January arrived on schedule on 7 July 2026, when the US Food and Drug Administration granted accelerated approval to Vera Therapeutics' atacicept-vymj, to be marketed as Trutakna, for...

AI Trust in Healthcare Starts with the People in the Room

Healthcare is on an accelerated path to digitisation, creating real opportunity to reduce administrative burden, improve risk detection, support prioritisation, and help people access the right care sooner. But without deliberate design, these same systems risk...

The Regulatory Window for AI in Pharmacovigilance Is Open

In more than two decades of working with global CROs, pharmaceutical companies, and biotech organizations, I have watched pharmacovigilance teams absorb wave after wave of increasing complexity. More products on the market. More data sources to monitor. More...

Webinar: Decoding Neurodegeneration via iPSC-Derived Human Brain Models

The human brain presents an intricate evolutionary paradox. While its sophisticated neural networks govern complex cognition, its architecture is uniquely susceptible to progressive degradation. For decades, the biomedical community has grappled with an uncomfortable...

Why the Immune System Is Becoming the New Battlefield in Cancer Care

The Old Paradigm For more than a century, cancer treatment has been defined by a straightforward objective: find the tumor and destroy it. Surgery removes it, radiation damages it. Chemotherapy attacks rapidly dividing cells. These approaches have saved countless...

CE Marking Is Not Enough: Three Layers for Connected Medical Devices

If your device connects to a network and runs AI, CE marking under MDR or IVDR is only the first layer for connected medical devices. Two further EU frameworks, the AI Act and the Cyber Resilience Act, can also apply, each with obligations that go beyond what MDR...

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.

See More Articles

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.